Digital Life Line Pte. Ltd. is a healthcare digitalization company that aims to transform the field of point-of-care testing by leveraging its proprietary on-kit signal amplification platform to enhance the detection sensitivity of rapid diagnostic kits, as well as an ecosystem of
scalable, serialized diagnostics to facilitate result tracing and reporting. We are focusing on the manufacturing and distribution of reader-free, low-cost signal amplification tools that can be seamlessly adapted to existing and future antigen rapid test (ART) kits for the healthcare industry and at-home testing.
AVAT is an self-automated visual acuity testing device that addresses the needs across public hospitals for fast and accurate screening measurements with smaller space occupancy.
AVAT (Automated Visual Acuity Testing) aims to decentralize eye screening and disease monitoring, meeting the rising demand for accessible care. By automating visual acuity tests, AVAT efficiently scales up testing, minimizes costs, and optimizes manpower resources. The device addresses current challenges by providing a streamlined, cost-effective, and accessible solution for widespread visual acuity testing.
DLL has licensed the saliva-based ART kit IP from Duke-NUS Medical School and SingHealth. The kit, known as Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), uses nanoparticles to bind the virus and uniquely, it also adds as a second type of nanoparticle that binds the first set of nanoparticles to amplify the signal. This makes testing using PASPORT more sensitive at finding and flagging the virus and allows it to be used at any time of the day, where the sensitivity of the test is not compromised even after eating or drinking. Compared to other ART, amplification enables PASPORT to be extremely sensitive. In a clinical study involving over 100 participants conducted at SGH, PASPORT’s sensitivity in detecting the virus was 97% and its specificity at 90.6%, compared to the gold standard PCR test. The invention was reviewed and published by Microchimica Acta* in November 2021.
*Microchimica Acta, established in 1937 by Fritz Pregl, is a monthly peer-reviewed scientific journal published by Springer Nature.
Leveraging on DiSa Serialization technology, the Company has developed, an automated recording ART (Antigen Rapid Test) Machine (“ChekPoint”) that is capable of reading the results of ART cassette and accordingly, authenticate and automate the delivery of tampered-free test results to the intended recipients or authorities.